Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CITY THERAPEUTICS, INC. (CTY)

City Therapeutics Doses First Participant in Phase 1 Trial of CITY-RBP4 for Stargardt

Neutral Impact 2 of 5 product/contract

City Therapeutics announced that the first participant has been dosed in a Phase 1 clinical trial of CITY-RBP4, an investigational RNAi therapeutic for Stargardt disease. The company expects to report initial data from the trial in mid-2027, and the filing contains no financial results, guidance or deal terms.

Key points

  • First participant dosed in Phase 1 trial of CITY-RBP4 for Stargardt disease type 1, announced November 10, 2026
  • City expects to report initial Phase 1 data in mid-2027
  • CITY-RBP4 is City's second program to enter the clinic; a third program is expected to enter the clinic through an investigator-initiated trial by year-end

The filing

CompanyCITY THERAPEUTICS, INC. (CTY)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:06 AM ET
Accession number0001104659-26-124775

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.